Naibec Announces 'Peptide Fusion Advanced Tissue Regeneration Bio-New Material Research Results'

[Asia Economy Reporter Jang Hyowon] Naivek, a peptide fusion bio-specialized company, announced on the 17th that it gave a presentation titled “Platform Operation Cases Related to Converged Medical Device Development” at the government-hosted ‘Medical Device R&D Integrated Conference.’

The Medical Device R&D Integrated Conference was hosted by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety, and was held at ‘El Tower’ under the supervision of the ‘Pan-Ministerial Full-Cycle Medical Device R&D Project Group (hereinafter Project Group).’

This event was held both online and offline under the theme “Next Normal and New Challenges, and Medical Device Integrated Platform,” with the Project Group providing seamless support throughout the full cycle of medical device R&D and commercialization success. It was an official occasion where the Project Group acted as a medical bridge to create a venue for industry-academia-research-hospital exchange, and it is evaluated as an integrated gathering where ▲hospitals ▲universities and research institutes ▲companies ▲R&D infrastructure support organizations ▲medical industry regulatory agencies come together as one system.

Naivek was selected as a presenter in the ‘Future Medical Environment Leading Medical Device Session’ at this event and presented on ‘Development of Peptide Fusion New Concept Tissue Regeneration Treatment Medical Devices.’ In this presentation, Naivek introduced the approval strategy, progress status, and commercialization strategy since last year’s selection of peptide fusion tissue regeneration biomaterial research as a pan-ministerial national project, receiving great response.

A Naivek official said, “Based on already successful cases of peptide fusion medical device development, we are currently developing cutting-edge converged medical devices under the government’s pan-ministerial research support,” adding, “This will greatly contribute to the company’s sales not only through finished product sales but also technology transfer as a surgical biomaterial applicable to various fields such as ▲musculoskeletal regeneration ▲nerve regeneration ▲vascular regeneration ▲dental treatment materials.”

Last year, Naivek was selected as both the lead and participating institution in the ‘4th Industrial Revolution and Future Medical Environment Leading Project’ field by the Project Group. With the selection of strategic tasks related to advanced tissue regeneration functional biomaterials and biosensors, Naivek will receive about 10 billion KRW in government support over a five-year research period. Naivek is currently conducting strategic tasks related to advanced tissue regeneration functional biomaterials and biosensors in a consortium with Seoul National University Dental Hospital and Pusan National University.